UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) March 7, 2005 (March 4, 2005)
PROTALEX, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 000-28385 | 91-2003490 |
| (Commission File Number) | (IRS Employer Identification No.) |
| 145 Union Square Drive, New Hope, PA | 18938 |
| (Address of Principal Executive Offices) | (Zip Code) |
215-862-9720
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8- Other Events
Item 8.01 Other Events.
On March 4, 2005, Protalex, Inc. filedan Investigational New Drug application with the U.S. Food and Drug Administration for a Phase I human clinical trial of PRTX-100 in patients with Rheumatoid Arthritis.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Protalex, Inc. (Registrant) | ||
| | | |
| Date: 3/7/05 | By: | /s/ Marc L. Rose |
By: Marc L. Rose Title: Vice President of Finance, Chief Financial Officer and Treasurer | ||